Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
Ludovic Helfgott, a Novo Nordisk executive, told Reuters during the European Association for the Study of Diabetes conference in Vienna: "We always presented it as a lottery ticket and it still is because it's very uncertain." The company is currently investigating whether semaglutide, the active ingredient found in popular medications Ozempic and Wegovy, can effectively slow cognitive decline in patients experiencing early-stage Alzheimers
And like most genes, this one varies from person to person
NEW BMS GUIDANCE: Managing HRT Alongside Incretin Therapies (Semaglutide, Tirzepatide)
Muscular fatigue investigated by phosphorus nuclear magnetic resonance